Fundraising FoxMaiabiotech
Chicago, US · 1 known investors
Find your way into Maiabiotech
Sign up to see every warm intro you have to Maiabiotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Maiabiotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MAIA Biotech is a clinical-stage biopharmaceutical company developing telomere-targeting cancer therapies, with a lead compound (THIO) based on a telomerase-targeting therapeutic approach. Its work spans oncology and nucleic acid-based therapeutics across multiple tumor types.
Founders & leadership
SM
Sergei M. GryaznovChief Scientific Officer
JC
Jeffrey C. HimmelreichHead of Finance
VV
Vlad VitocChief Executive Officer and Chairman
NY
Ngar Yee LouieNamed on SEC filing
Board
CL
Cristian LuputBoard director
JT
Jean-Manasse TheageneBoard director
RG
Ramiro GuerreroBoard director
SC
Steven ChaoukiBoard director
SS
Stan SmithBoard director
LN
Louie Ngar YeeBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$19.6M disclosed across 7 rounds · 2023–2025
▶$1.5MraisedJan 2026 · 17 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJan 2026 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sergei GryaznovExecutive Officer
- Jean-Manasse TheageneDirector
- Ramiro GuerreroDirector
- Stan SmithDirector
- Cristian LuputDirector
- Vlad VitocExecutive Officer, Director
- Jeffrey HimmelreichExecutive Officer, Director
- Steven ChaoukiDirector
- Louie Ngar YeeDirector
- Offering amount
- $2M
- Amount sold
- $1.5M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedOct 2025 · 17 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louie Ngar YeeDirector
- Steven ChaoukiDirector
- Stan SmithDirector
- Sergei GryaznovExecutive Officer
- Jeffrey HimmelreichExecutive Officer
- Vlad VitocExecutive Officer, Director
- Ramiro GuerreroDirector
- Jean-Manasse TheageneDirector
- Cristian LuputDirector
- Offering amount
- $7M
- Amount sold
- $3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$695KraisedJun 2025 · 11 investors · BiotechnologyRule 506(b)
▶$695KraisedJun 2025 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ramiro GuerreroDirector
- Jean-Manasse TheageneDirector
- Louie Ngar YeeDirector
- Vlad VitocExecutive Officer, Director
- Cristian LuputDirector
- Jeffrey HimmelreichExecutive Officer
- Steven ChaoukiDirector
- Stan SmithDirector
- Sergei GryaznovExecutive Officer
- Offering amount
- $8M
- Amount sold
- $695K
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedMar 2025 · 43 investors · BiotechnologyRule 506(b)
▶$4.1MraisedMar 2025 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cristian LuputDirector
- Jeffrey HimmelreichExecutive Officer
- Stan SmithDirector
- Vlad VitocExecutive Officer, Director
- Ramiro GuerreroDirector
- Steven ChaoukiDirector
- Louie Ngar YeeDirector
- Sergei GryaznovExecutive Officer
- Jean-Manasse TheageneDirector
- Offering amount
- $5.9M
- Amount sold
- $4.1M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedNov 2024 · 21 investors · BiotechnologyRule 506(b)
▶$2.4MraisedNov 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cristian LuputDirector
- Jean-Manasse TheageneDirector
- Jeffrey HimmelreichExecutive Officer
- Ramiro GuerreroDirector
- Steven ChaoukiDirector
- Sergei GryaznovExecutive Officer
- Vlad VitocExecutive Officer, Director
- Stan SmithDirector
- Louie Ngar YeeDirector
- Offering amount
- $15.5M
- Amount sold
- $2.4M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedMar 2024 · 19 investors · BiotechnologyRule 506(b)
▶$2.9MraisedMar 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey HimmelreichExecutive Officer
- Stan V. SmithDirector
- Cristian LuputDirector
- Steven ChaoukiDirector
- Sergei GryaznovExecutive Officer
- Ngar Yee LouieDirector
- Ramiro GuerreroDirector
- Vlad VitocExecutive Officer, Director
- Jean-Manasse TheageneDirector
- Offering amount
- $5.7M
- Amount sold
- $2.9M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.9MraisedNov 2023 · 3 investors · BiotechnologyRule 506(b)
▶$4.9MraisedNov 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cristian LuputDirector
- Stan SmithDirector
- Vlad VitocExecutive Officer, Director
- Jeffrey C HimmelreichExecutive Officer
- Ramiro GuerreroDirector
- Sergei GryaznovExecutive Officer
- Steven M ChaoukiDirector
- Ngar Yee LouieDirector
- Jean-Manasse TheageneDirector
- Offering amount
- $4.9M
- Amount sold
- $4.9M
- Sales commissions
- $280K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
KrakenKraken 360 Investments provides capital and launch infrastructure to blockchain protocols in pre-token and early post-token phases, offering custody, staking, treasury, and liquidity services alongside fundraising support.
TipRanksFinancial analysis and stock research platform.
Companies working in the same space as Maiabiotech.
Frequently asked questions
- What does Maiabiotech do?
- MAIA Biotech is a clinical-stage biopharmaceutical company developing telomere-targeting cancer therapies, with a lead compound (THIO) based on a telomerase-targeting therapeutic approach. Its work spans oncology and nucleic acid-based therapeutics across multiple tumor types.
- Who are Maiabiotech's investors?
- Maiabiotech's investors include Checkmate Capital Group LLC.
- How much funding has Maiabiotech raised?
- Maiabiotech has disclosed $19.6M raised across 7 rounds.
- Where is Maiabiotech headquartered?
- Maiabiotech is headquartered in Chicago, US.